Bayer Schering Pharma Ag

Evestra, Inc.

Thommen Medical Ag

Julius-maximilians-universitaet

Berlirem Gmbh

Julius-maximilians-universitaet Wuerzburg

Verein Zur Förderung Von Innovationen Durch Forschung, Entwicklung Und Technologietransfer E.v. (verein Innovent E.v.)

Ralf Wyrwa

Walter Elger

Klaus Nickisch

Sven Ring

Matthias Schnabelrauch

Birgitt Schneider

Bindu Santhamma

Hareesh Nair

Lorenz Meinel

Frederick Meece

Gulzar Ahmed

Alexander Hillisch

Falko Schlottig

Peter Droescher

Johannes Wilhelm Tack

Guenter Kaufmann

Gudrun Reddersen

Matthias Schnalbelrauch

Jennifer Ritzer

Claudia Rode

Thomas Seemann

Christoph Voelkel

Thorsten Laube

Juergen Weisser

Johannes Tack

Jürgen Schmidt

Jürgen Weisser

Christoph VÖLKEL

Angelika Henning

Christian Schrader

It is an object of the present invention to introduce carboxylic acid-functionalities suitable for coupling into the denatonium structure by means of simple synthesis, namely the synthesis of bitter principle derivatives based on the denatonium structure according to formula 1: For example, according to the invention, lidocaine derivatives may be reacted with carboxylated benzyl halogenides. The carboxylated denatonium derivatives of the present invention are especially applied in medicine, biology, medical engineering as well as cosmetics, the pharmaceutical, chemical, and foodstuff industry.

Production of bitter principle derivatives

The present invention relates to novel compounds of the formula I, methods for their preparation and their use for treatment of diseases. The invention discloses the synthesis of levodopa (L-DOPA) esters by coupling polyhydroxy compounds or their derivatives to the L-DOPA carboxyl group. The synthesis allows to produce L-DOPA derivatives which are highly soluble in water as well as aqueous and biocompatible liquids and have an improved hydrolytic stability in water or aqueous and biocompatible media for an application over several days. The invention helps producing L-DOPA substances for applications in the fields of medicine, biology and medical engineering as well as in the pharmaceutical industry.

Water-soluble L-DOPA esters

Various prodrug compounds having the general structure: Active agent&#x2014;(acid)-(linker)&#x2014;SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

Pro-drug forming compounds

Various prodrug compounds having the general structure: Active agent-(acid)-(linker)-SONRRare described herein. Compounds having this general structure were shown to be more orally active than the unmodified parent molecule.

The document proposes a diagnostic chewing gum for identifying the presence of inflammatory tissues in the mouth, in particular in or adjacent to the mandible, the maxilla, an implant or the teeth of a user, comprising a base material or particles () embedded and/or attached to the base material; an element (,-), like e.g. a releasable flavor molecule, attached to the base material and/or the particles, for the generation of a change in the chewing gum directly detectable by the user; wherein the element (,-) generates the change upon direct or indirect contact with a marker (), e.g. a proteolytic enzyme, which is released by inflammatory tissue in response to bacterial mediators.

Device for the diagnosis of inflammatory tissues in dental applications

The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with estrogenic action.

Estradiol prodrugs

The invention relates to &#x394;-D-homosteroids of general formula (I) process for their production and pharmaceutical compositions that contain these compounds. The compounds of general formula I according to the invention have androgenic activity.

[object Object]

Growing community of inventors

Rothenstein, Germany

Ralf Wyrwa